Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alcon, a global eye care company, has received regulatory approval to acquire the rights of Durezol emulsion in the US and the global rights, excluding Latin America, for Zyclorin from Sirion Therapeutics.
Subscribe to our email newsletter
Alcon is expected to immediately assume all marketing, promotion and sales of Durezol. The management of Alcon is continuing to evaluate options to acquire Zirgan, an antiviral recently approved by the FDA for the treatment of acute herpetic keratitis.
Durezol emulsion is a topical ophthalmic corticosteroid used to treat postoperative inflammation and pain associated with ocular surgery and received approval from the FDA in 2008.
Currently under clinical investigation to treat dry eye and other ocular surface diseases, Zyclorin is a topical ophthalmic immunomodulator and immunosuppressive agent.
Stuart Raetzman, vice president of global marketing and area president for the US at Alcon, said: “This acquisition reinforces our ability to drive growth in the near-term with the acquisition of Durezol and add products to our long-term research pipeline with Zyclorin.
“Durezol’s unique capability to effectively and quickly treat both inflammation and pain following ocular surgery makes it a great fit for Alcon’s leading product portfolio.”